Table 1.
Characteristics of hematopoietic stem cell transplantation (HSCT) patients.
| Diagnosis | Age (y) | Gender | Donor | HLA Sero Compatibility | Stem Cell Source | Conditioning | GVHD Prophylaxis | Days of LA GVHD Onset | Days of Sampling | Target Organ | Grade | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Late-Onset Acute GVHD Group | ||||||||||||
| PN 1 | AML | 33 | M | Matched unrelated | 6/6 | BM | Myeloablative | CsA + st-MTX | +238 | +248 | Liver | IV |
| PN 2 | NHL | 38 | M | Matched related | 6/6 | PBSC | Reduced intensity | CsA + st-MTX | +180 | +221 | Liver | IV |
| PN 3 | AML | 57 | M | Mismatched | 5/6 | BM | Myeloablative | Tac + st-MTX | +117 | +136 | Gut | III |
| PN 4 | ALL | 56 | F | Mismatched | 4/6 | Umbilical cord blood | Myeloablative | Tac | +119 | +132 | Skin + gut | IV |
| PN 5 | ALL | 60 | F | Mismatched | 4/6 | Umbilical cord blood | Myeloablative | Tac | +165 | +174 | gut | II |
| Non-GVHD Group | ||||||||||||
| PN 6 | ALL | 62 | M | Matched unrelated | 6/6 | BM | Reduced intensity | CsA + st-MTX | +42 | |||
| PN 7 | ALL | 26 | F | Matched unrelated | 6/6 | BM | Myeloablative | CsA + st-MTX | +41 | |||
| PN 8 | AML | 60 | M | Mismatched | 4/6 | Umbilical cord blood | Myeloablative | Tac | +49 | |||
| PN 9 | AML | 62 | M | Mismatched | 5/6 | PBSC | Reduced intensity | Tac + st-MTX | +41 | |||
| PN 10 | AML | 70 | F | Mismatched | 4/6 | Umbilical cord blood | Reduced intensity | Tac | +45 | |||
AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; BM, bone marrow; PBSC, peripheral blood stem cell; CsA, cyclosporine A; Tac, tacrolimus; MTX, methotrexate.